AMENDMENT AGREEMENTAmendment Agreement • September 17th, 2021 • Cellect Biotechnology Ltd. • Surgical & medical instruments & apparatus • New York
AMENDMENT AGREEMENT (this "Agreement"), dated as of September [●], 2021 by and among Quoin Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 42127 Pleasant Forest Ct, Ashburn, VA 20148 ("Quoin"), Cellect Biotechnology Ltd., an Israeli company, with headquarters located at 23 Hata'as Street, Kfar Saba, Israel 44425 ("Cellect") and the investor listed on the signature page attached hereto (the "Holder"). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Primary Financing SPA, the Bridge SPA, the RRA or the Warrants (each as defined below), as applicable.
QUOIN PHARMACEUTICALS, INC.Cellect Biotechnology Ltd. • September 17th, 2021 • Surgical & medical instruments & apparatus
Reference is hereby made to the Agreement and Plan of Merger and Reorganization, dated March 24, 2021 (the “Agreement”), by and among Cellect Biotechnology Ltd., an Israeli company (“Cellect”), CELLMSC, Inc., a Delaware corporation (“Merger Sub”), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
